The battle lines have been drawn between Bristol-Myers Squibb Co. and Exelixis Inc. and partner Ipsen after strong data presented at the recent European Society for Medical Oncology congress in Madrid on their respective first-line renal cell carcinoma therapies saw both being touted as potentially practice-changing.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?